Wang JX - Search Results

1

[Anti-tumor mechanism of traditional Chinese medicine via Hedgehog signaling pathway: a review].

Wang JX, Shi Q, Zhang ZL, Wu QS. Wang JX, et al. Zhongguo Zhong Yao Za Zhi. 2024 Nov;49(21):5771-5796. doi: 10.19540/j.cnki.cjcmm.20240809.601. Zhongguo Zhong Yao Za Zhi. 2024. PMID: 39701788 Review. Chinese.

2

Cryptotanshinone inhibits ovarian tumor growth and metastasis by degrading c-Myc and attenuating the FAK signaling pathway.

Guo H, Zhang W, Wang J, Zhao G, Wang Y, Zhu BM, Dong P, Watari H, Wang B, Li W, Tigyi G, Yue J. Guo H, et al. Front Cell Dev Biol. 2022 Sep 28;10:959518. doi: 10.3389/fcell.2022.959518. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 36247016 Free PMC article.

3

CD25: A potential tumor therapeutic target.

Peng Y, Tao Y, Zhang Y, Wang J, Yang J, Wang Y. Peng Y, et al. Int J Cancer. 2023 Apr 1;152(7):1290-1303. doi: 10.1002/ijc.34281. Epub 2022 Oct 1. Int J Cancer. 2023. PMID: 36082452 Review.

4

Small-Molecule Modulators Targeting Toll-like Receptors for Potential Anticancer Therapeutics.

Wang J, Zhang J, Wang J, Hu X, Ouyang L, Wang Y. Wang J, et al. J Med Chem. 2023 May 25;66(10):6437-6462. doi: 10.1021/acs.jmedchem.2c01655. Epub 2023 May 10. J Med Chem. 2023. PMID: 37163340 Review.

5

GG-NER's role in androgen receptor signaling inhibitor response for advanced prostate cancer.

Zhong C, Wang J, Peng H, Lu J, Long Z, Lin Z, Chen G, Cai C, Cheng S, Chen Z, Zhang L, Zhong W, Mo R, Mao X. Zhong C, et al. Cell Commun Signal. 2024 Dec 18;22(1):600. doi: 10.1186/s12964-024-01977-0. Cell Commun Signal. 2024. PMID: 39696559 Free PMC article.

6

Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions.

Xiong L, Zhang Y, Wang J, Yu M, Huang L, Hou Y, Li G, Wang L, Li Y. Xiong L, et al. Eur J Med Chem. 2024 Mar 5;267:116158. doi: 10.1016/j.ejmech.2024.116158. Epub 2024 Jan 17. Eur J Med Chem. 2024. PMID: 38278080 Free article. Review.

7

Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects.

Chen Y, Wang Y, Wang J, Zhou Z, Cao S, Zhang J. Chen Y, et al. J Med Chem. 2023 Feb 23;66(4):2257-2281. doi: 10.1021/acs.jmedchem.2c01523. Epub 2023 Feb 6. J Med Chem. 2023. PMID: 36745746 Review.

8

Targeting FGFRs for tumor therapy: current status and novel strategies.

Dong Y, Ren C, Zhu M, Zhang D, Wang T, Zhang J, Wang J, Mao W, Long F. Dong Y, et al. Future Med Chem. 2022 Dec;14(24):1923-1941. doi: 10.4155/fmc-2022-0194. Epub 2022 Nov 30. Future Med Chem. 2022. PMID: 36449352 Review.

9

Recent advances of human dihydroorotate dehydrogenase inhibitors for cancer therapy: Current development and future perspectives.

Zhang L, Zhang J, Wang J, Ren C, Tang P, Ouyang L, Wang Y. Zhang L, et al. Eur J Med Chem. 2022 Mar 15;232:114176. doi: 10.1016/j.ejmech.2022.114176. Epub 2022 Feb 3. Eur J Med Chem. 2022. PMID: 35151222 Review.

10

Strategies of targeting CYP51 for IFIs therapy: Emerging prospects, opportunities and challenges.

Zhang R, Wang Y, Wu A, Wang J, Zhang J. Zhang R, et al. Eur J Med Chem. 2023 Nov 5;259:115658. doi: 10.1016/j.ejmech.2023.115658. Epub 2023 Jul 17. Eur J Med Chem. 2023. PMID: 37480712 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,173 results

Search Page

Filters